25 XP   0   0   10

Replimune Group Inc
Buy, Hold or Sell?

Let's analyse Replimune together

PenkeI guess you are interested in Replimune Group Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Replimune Group Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Replimune Group Inc

I send you an email if I find something interesting about Replimune Group Inc.

Quick analysis of Replimune (30 sec.)










What can you expect buying and holding a share of Replimune? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
3.6%

What is your share worth?

Current worth
$6.33
Expected worth in 1 year
$2.95
How sure are you?
21.4%

+ What do you gain per year?

Total Gains per Share
$-3.37
Return On Investment
-41.3%

For what price can you sell your share?

Current Price per Share
$8.17
Expected price per share
$5.89 - $9.5
How sure are you?
50%

1. Valuation of Replimune (5 min.)




Live pricePrice per Share (EOD)

$8.17

Intrinsic Value Per Share

$-38.65 - $-45.71

Total Value Per Share

$-32.33 - $-39.38

2. Growth of Replimune (5 min.)




Is Replimune growing?

Current yearPrevious yearGrowGrow %
How rich?$421.5m$450.2m$38.7m7.9%

How much money is Replimune making?

Current yearPrevious yearGrowGrow %
Making money-$52.4m-$39.1m-$13.3m-25.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Replimune (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#137 / 1031

Most Revenue
#840 / 1031

Most Profit
#928 / 1031

Most Efficient
#286 / 1031

What can you expect buying and holding a share of Replimune? (5 min.)

Welcome investor! Replimune's management wants to use your money to grow the business. In return you get a share of Replimune.

What can you expect buying and holding a share of Replimune?

First you should know what it really means to hold a share of Replimune. And how you can make/lose money.

Speculation

The Price per Share of Replimune is $8.17. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Replimune.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Replimune, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.33. Based on the TTM, the Book Value Change Per Share is $-0.84 per quarter. Based on the YOY, the Book Value Change Per Share is $0.64 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Replimune.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.77-9.4%-0.80-9.8%-0.64-7.8%-0.47-5.8%-0.36-4.4%
Usd Book Value Change Per Share-0.66-8.1%-0.84-10.3%0.647.9%0.202.4%0.232.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.66-8.1%-0.84-10.3%0.647.9%0.202.5%0.232.8%
Usd Price Per Share8.43-16.61-19.73-21.26-16.12-
Price to Earnings Ratio-2.75--5.20--7.81--14.62--12.52-
Price-to-Total Gains Ratio-12.75--19.42--295.48--106.40--100.60-
Price to Book Ratio1.33-2.19-2.68-4.00-3.24-
Price-to-Total Gains Ratio-12.75--19.42--295.48--106.40--100.60-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.17
Number of shares122
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.840.20
Usd Total Gains Per Share-0.840.20
Gains per Quarter (122 shares)-102.8824.50
Gains per Year (122 shares)-411.5198.01
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-412-42219788
20-823-8341195186
30-1235-12462292284
40-1646-16582390382
50-2058-20703487480
60-2469-24824584578
70-2881-28944682676
80-3292-33065779774
90-3704-37186877872
100-4115-41306974970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.026.00.07.1%2.026.00.07.1%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%6.019.03.021.4%6.019.03.021.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%1.00.027.03.6%1.00.027.03.6%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%6.019.03.021.4%6.019.03.021.4%

Fundamentals of Replimune

About Replimune Group Inc

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Fundamental data was last updated by Penke on 2024-03-22 02:01:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Replimune Group Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Replimune earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Replimune to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Replimune Group Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM--202.3%+202.3%
YOY--263.0%+263.0%
5Y--452.4%+452.4%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Replimune is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Replimune to the Biotechnology industry mean.
  • -9.6% Return on Assets means that Replimune generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Replimune Group Inc:

  • The MRQ is -9.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.6%TTM-9.0%-0.6%
TTM-9.0%YOY-8.0%-1.1%
TTM-9.0%5Y-6.8%-2.2%
5Y-6.8%10Y-9.3%+2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.6%-12.5%+2.9%
TTM-9.0%-12.2%+3.2%
YOY-8.0%-11.2%+3.2%
5Y-6.8%-13.3%+6.5%
10Y-9.3%-14.6%+5.3%
1.1.3. Return on Equity

Shows how efficient Replimune is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Replimune to the Biotechnology industry mean.
  • -12.1% Return on Equity means Replimune generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Replimune Group Inc:

  • The MRQ is -12.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.1%TTM-10.9%-1.2%
TTM-10.9%YOY-9.0%-1.9%
TTM-10.9%5Y-8.0%-2.9%
5Y-8.0%10Y-9.0%+1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.1%-16.0%+3.9%
TTM-10.9%-15.8%+4.9%
YOY-9.0%-13.9%+4.9%
5Y-8.0%-18.2%+10.2%
10Y-9.0%-19.1%+10.1%

1.2. Operating Efficiency of Replimune Group Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Replimune is operating .

  • Measures how much profit Replimune makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Replimune to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Replimune Group Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM--208.5%+208.5%
YOY--280.2%+280.2%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Replimune is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Replimune Group Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM-3.181-3.181
YOY-3.609-3.609
5Y-5.554-5.554
10Y-7.396-7.396

1.3. Liquidity of Replimune Group Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Replimune is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.40 means the company has $12.40 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Replimune Group Inc:

  • The MRQ is 12.398. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.934. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.398TTM14.934-2.536
TTM14.934YOY19.737-4.803
TTM14.9345Y19.764-4.830
5Y19.76410Y18.214+1.550
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.3983.987+8.411
TTM14.9344.440+10.494
YOY19.7375.569+14.168
5Y19.7646.158+13.606
10Y18.2146.492+11.722
1.3.2. Quick Ratio

Measures if Replimune is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Replimune to the Biotechnology industry mean.
  • A Quick Ratio of 21.72 means the company can pay off $21.72 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Replimune Group Inc:

  • The MRQ is 21.716. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 26.326. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.716TTM26.326-4.610
TTM26.326YOY33.363-7.037
TTM26.3265Y32.145-5.819
5Y32.14510Y29.574+2.570
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.7163.653+18.063
TTM26.3264.158+22.168
YOY33.3635.515+27.848
5Y32.1456.012+26.133
10Y29.5746.206+23.368

1.4. Solvency of Replimune Group Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Replimune assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Replimune to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.21 means that Replimune assets are financed with 20.9% credit (debt) and the remaining percentage (100% - 20.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Replimune Group Inc:

  • The MRQ is 0.209. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.168. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.209TTM0.168+0.041
TTM0.168YOY0.114+0.054
TTM0.1685Y0.136+0.032
5Y0.13610Y0.227-0.091
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2090.336-0.127
TTM0.1680.330-0.162
YOY0.1140.267-0.153
5Y0.1360.367-0.231
10Y0.2270.378-0.151
1.4.2. Debt to Equity Ratio

Measures if Replimune is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Replimune to the Biotechnology industry mean.
  • A Debt to Equity ratio of 26.4% means that company has $0.26 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Replimune Group Inc:

  • The MRQ is 0.264. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.203. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.264TTM0.203+0.061
TTM0.203YOY0.129+0.074
TTM0.2035Y0.161+0.043
5Y0.16110Y0.132+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2640.376-0.112
TTM0.2030.398-0.195
YOY0.1290.334-0.205
5Y0.1610.431-0.270
10Y0.1320.476-0.344

2. Market Valuation of Replimune Group Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Replimune generates.

  • Above 15 is considered overpriced but always compare Replimune to the Biotechnology industry mean.
  • A PE ratio of -2.75 means the investor is paying $-2.75 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Replimune Group Inc:

  • The EOD is -2.663. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.748. Based on the earnings, the company is expensive. -2
  • The TTM is -5.204. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.663MRQ-2.748+0.085
MRQ-2.748TTM-5.204+2.456
TTM-5.204YOY-7.809+2.606
TTM-5.2045Y-14.620+9.416
5Y-14.62010Y-12.523-2.097
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.663-2.697+0.034
MRQ-2.748-2.422-0.326
TTM-5.204-2.709-2.495
YOY-7.809-4.116-3.693
5Y-14.620-6.257-8.363
10Y-12.523-6.478-6.045
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Replimune Group Inc:

  • The EOD is -2.787. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.876. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.334. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.787MRQ-2.876+0.089
MRQ-2.876TTM-6.334+3.458
TTM-6.334YOY-10.243+3.909
TTM-6.3345Y-16.695+10.361
5Y-16.69510Y-14.120-2.574
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.787-3.344+0.557
MRQ-2.876-2.939+0.063
TTM-6.334-3.486-2.848
YOY-10.243-5.592-4.651
5Y-16.695-8.464-8.231
10Y-14.120-8.872-5.248
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Replimune is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.33 means the investor is paying $1.33 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Replimune Group Inc:

  • The EOD is 1.292. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.333. Based on the equity, the company is underpriced. +1
  • The TTM is 2.190. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.292MRQ1.333-0.041
MRQ1.333TTM2.190-0.857
TTM2.190YOY2.679-0.489
TTM2.1905Y3.996-1.806
5Y3.99610Y3.243+0.753
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2922.198-0.906
MRQ1.3332.042-0.709
TTM2.1902.121+0.069
YOY2.6792.907-0.228
5Y3.9963.682+0.314
10Y3.2434.114-0.871
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Replimune Group Inc.

3.1. Institutions holding Replimune Group Inc

Institutions are holding 109.038% of the shares of Replimune Group Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baker Bros Advisors LP15.54920.915695453364967056108.4917
2023-12-31T. Rowe Price Associates, Inc.9.52840.00665849251560520.9675
2023-12-31State Street Corporation8.32660.002151115212740876115.6173
2023-12-31BlackRock Inc7.39310.001453848758054114.6677
2023-12-31Goldman Sachs Group Inc7.29420.003444777663918436700.5589
2023-12-31Morgan Stanley - Brokerage Accounts7.24450.003344472283977869847.511
2023-09-30Redmile Group, LLC6.7833.38984163922-256611-5.805
2023-09-30Omega Fund Management LLC4.889147.1663300131900
2023-12-31Vanguard Group Inc4.45980.000527377731416545.4564
2023-09-30Bvf Inc3.4910.9888214303600
2023-12-31Dimensional Fund Advisors, Inc.2.15510.00331322969-107056-7.4863
2023-09-30Citadel Advisors Llc1.950.00441197035609175.3619
2023-12-31Geode Capital Management, LLC1.86540.001114511213676913.5637
2023-12-31Camber Capital Management LLC1.6290.21481000000-1000000-50
2023-12-31FMR Inc1.34530.0005825861-442822-34.9041
2023-12-31Emerald Advisers, LLC0.87780.1944538841-513683-48.8049
2023-12-31Artal Group S A0.81450.140150000000
2023-09-30BRAIDWELL LP0.79420.263648752000
2023-12-31Northern Trust Corp0.78490.0007481834290916.4255
2023-12-31Rafferty Asset Management, LLC0.75490.0165463397276596148.0699
Total 87.9353.316753978208+14565685+27.0%

3.2. Funds holding Replimune Group Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31SPDR® S&P Biotech ETF6.5930.47434047274-53600-1.307
2023-12-31T. Rowe Price New Horizons3.96980.0832436983-7791-0.3187
2023-12-31US Small-Cap Growth II Equity Comp3.96980.08282436983-8631-0.3529
2023-12-31T. Rowe Price Health Sciences2.42940.08551491344-29312-1.9276
2024-01-31Vanguard Total Stock Mkt Idx Inv2.41740.0008148398000
2024-01-31iShares Russell 2000 ETF1.94940.01541196690-21774-1.787
2023-12-31Fidelity Select Biotechnology1.34410.151282511500
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr1.29290.00647936633980.0502
2023-12-31T. Rowe Price Integrated US Sm Gr Eq0.76350.050746866600
2024-01-31iShares Russell 2000 Value ETF0.75150.0306461355-876-0.1895
2024-01-31Direxion Daily S&P Biotech Bull 3X ETF0.72480.329244491400
2023-12-31T. Rowe Price New Horizons Tr-Z0.68940.082442322877911.8754
2023-11-30Fidelity Small Cap Index0.6640.020540759483342.0874
2024-01-31iShares Biotechnology ETF0.530.0344325331-298-0.0915
2024-01-31State St Russell Sm/Mid Cp® Indx NL Cl C0.48120.00629539300
2023-12-31Fidelity Extended Market Index0.46680.0067286543-719-0.2503
2023-12-31DFA US Micro Cap I0.40960.029925142800
2024-01-31Schwab US Small-Cap ETF™0.38270.011923495000
2023-09-30Loomis Sayles Small Cap Growth CIT D0.31980.59921963481963480
2024-01-31Dimensional US Core Equity 2 ETF0.30140.005918500800
Total 30.45052.106818692790+89870+0.5%

3.3. Insider Transactions

Insiders are holding 7.351% of the shares of Replimune Group Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-16Konstantinos XynosSELL731310.92
2023-09-11Pamela EspositoSELL535820.01
2023-08-22Pamela EspositoSELL1860020.01
2023-08-11Pamela EspositoSELL140020
2023-07-10Pamela EspositoSELL2000021.58
2023-06-13Tanya LewisSELL1286024.06
2023-05-16Colin LoveSELL1077518.05
2023-05-16Jean M FranchiSELL1135118.05
2023-05-16Philip Astley-sparkeSELL1790218.05
2023-05-16Sushil PatelSELL1557518.05

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Replimune Group Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.661-0.843+28%0.643-203%0.200-431%0.226-393%
Book Value Per Share--6.3257.493-16%7.334-14%5.977+6%4.448+42%
Current Ratio--12.39814.934-17%19.737-37%19.764-37%18.214-32%
Debt To Asset Ratio--0.2090.168+24%0.114+83%0.136+54%0.227-8%
Debt To Equity Ratio--0.2640.203+30%0.129+105%0.161+65%0.132+100%
Dividend Per Share----0%-0%0.001-100%0.001-100%
Eps---0.767-0.803+5%-0.638-17%-0.473-38%-0.360-53%
Free Cash Flow Per Share---0.733-0.671-8%-0.493-33%-0.395-46%-0.308-58%
Free Cash Flow To Equity Per Share---0.510-0.610+20%0.777-166%0.261-295%0.260-296%
Gross Profit Margin--1.0001.046-4%1.0000%1.009-1%1.007-1%
Intrinsic Value_10Y_max---45.707--------
Intrinsic Value_10Y_min---38.654--------
Intrinsic Value_1Y_max---2.354--------
Intrinsic Value_1Y_min---2.311--------
Intrinsic Value_3Y_max---8.769--------
Intrinsic Value_3Y_min---8.338--------
Intrinsic Value_5Y_max---17.230--------
Intrinsic Value_5Y_min---15.846--------
Market Cap501538326.000-12%561823175.1301085537928.333-48%1211334763.500-54%1318159166.467-57%998764461.048-44%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.292-3%1.3332.190-39%2.679-50%3.996-67%3.243-59%
Pe Ratio-2.663+3%-2.748-5.204+89%-7.809+184%-14.620+432%-12.523+356%
Price Per Share8.170-3%8.43016.605-49%19.733-57%21.257-60%16.116-48%
Price To Free Cash Flow Ratio-2.787+3%-2.876-6.334+120%-10.243+256%-16.695+481%-14.120+391%
Price To Total Gains Ratio-12.353+3%-12.746-19.423+52%-295.480+2218%-106.403+735%-100.597+689%
Quick Ratio--21.71626.326-18%33.363-35%32.145-32%29.574-27%
Return On Assets---0.096-0.090-6%-0.080-17%-0.068-29%-0.093-3%
Return On Equity---0.121-0.109-10%-0.090-26%-0.080-34%-0.090-26%
Total Gains Per Share---0.661-0.843+28%0.643-203%0.201-429%0.227-392%
Usd Book Value--421537000.000489007500.000-14%450227000.000-6%372747100.000+13%277208071.429+52%
Usd Book Value Change Per Share---0.661-0.843+28%0.643-203%0.200-431%0.226-393%
Usd Book Value Per Share--6.3257.493-16%7.334-14%5.977+6%4.448+42%
Usd Dividend Per Share----0%-0%0.001-100%0.001-100%
Usd Eps---0.767-0.803+5%-0.638-17%-0.473-38%-0.360-53%
Usd Free Cash Flow---48842000.000-44067500.000-10%-30245500.000-38%-24840650.000-49%-19299107.143-60%
Usd Free Cash Flow Per Share---0.733-0.671-8%-0.493-33%-0.395-46%-0.308-58%
Usd Free Cash Flow To Equity Per Share---0.510-0.610+20%0.777-166%0.261-295%0.260-296%
Usd Market Cap501538326.000-12%561823175.1301085537928.333-48%1211334763.500-54%1318159166.467-57%998764461.048-44%
Usd Price Per Share8.170-3%8.43016.605-49%19.733-57%21.257-60%16.116-48%
Usd Profit---51120000.000-52489500.000+3%-39185250.000-23%-29659500.000-42%-23017357.143-55%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.661-0.843+28%0.643-203%0.201-429%0.227-392%
 EOD+3 -5MRQTTM+12 -18YOY+3 -265Y+6 -2610Y+7 -25

4.2. Fundamental Score

Let's check the fundamental score of Replimune Group Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.663
Price to Book Ratio (EOD)Between0-11.292
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than121.716
Current Ratio (MRQ)Greater than112.398
Debt to Asset Ratio (MRQ)Less than10.209
Debt to Equity Ratio (MRQ)Less than10.264
Return on Equity (MRQ)Greater than0.15-0.121
Return on Assets (MRQ)Greater than0.05-0.096
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Replimune Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.577
Ma 20Greater thanMa 508.523
Ma 50Greater thanMa 1008.098
Ma 100Greater thanMa 2008.751
OpenGreater thanClose8.230
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets532,930
Total Liabilities111,393
Total Stockholder Equity421,537
 As reported
Total Liabilities 111,393
Total Stockholder Equity+ 421,537
Total Assets = 532,930

Assets

Total Assets532,930
Total Current Assets479,164
Long-term Assets53,766
Total Current Assets
Cash And Cash Equivalents 97,672
Short-term Investments 368,679
Net Receivables 4,295
Other Current Assets 8,518
Total Current Assets  (as reported)479,164
Total Current Assets  (calculated)479,164
+/-0
Long-term Assets
Property Plant Equipment 52,130
Long-term Assets Other 1,636
Long-term Assets  (as reported)53,766
Long-term Assets  (calculated)53,766
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities38,650
Long-term Liabilities72,743
Total Stockholder Equity421,537
Total Current Liabilities
Short-term Debt 3,861
Accounts payable 3,903
Other Current Liabilities 3,561
Total Current Liabilities  (as reported)38,650
Total Current Liabilities  (calculated)11,325
+/- 27,325
Long-term Liabilities
Long term Debt 44,434
Capital Lease Obligations Min Short Term Debt27,516
Long-term Liabilities Other 793
Long-term Liabilities  (as reported)72,743
Long-term Liabilities  (calculated)72,743
+/-0
Total Stockholder Equity
Common Stock61
Retained Earnings -646,207
Accumulated Other Comprehensive Income 4,734
Other Stockholders Equity 1,062,949
Total Stockholder Equity (as reported)421,537
Total Stockholder Equity (calculated)421,537
+/-0
Other
Capital Stock61
Cash and Short Term Investments 466,351
Common Stock Shares Outstanding 66,646
Current Deferred Revenue27,325
Liabilities and Stockholders Equity 532,930
Net Debt -21,861
Net Invested Capital 465,971
Net Working Capital 440,514
Property Plant and Equipment Gross 61,322
Short Long Term Debt Total 75,811



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
> Total Assets 
22,819
0
0
0
65,151
59,293
153,816
152,187
154,326
143,541
151,438
250,423
234,097
329,583
314,244
559,198
543,098
523,724
503,464
485,282
461,192
459,427
436,095
678,550
646,591
603,891
562,398
532,930
532,930562,398603,891646,591678,550436,095459,427461,192485,282503,464523,724543,098559,198314,244329,583234,097250,423151,438143,541154,326152,187153,81659,29365,15100022,819
   > Total Current Assets 
22,402
0
0
0
64,703
55,224
151,867
144,946
140,981
127,738
118,012
190,874
174,251
267,741
252,414
499,428
483,747
464,563
444,384
427,795
403,977
401,947
379,390
623,961
592,603
550,042
508,175
479,164
479,164508,175550,042592,603623,961379,390401,947403,977427,795444,384464,563483,747499,428252,414267,741174,251190,874118,012127,738140,981144,946151,86755,22464,70300022,402
       Cash And Cash Equivalents 
20,594
0
0
0
17,583
12,910
23,282
21,052
25,704
38,364
53,298
63,002
59,500
104,797
43,326
324,475
182,518
192,528
159,969
132,275
105,948
112,245
88,930
206,667
146,590
106,481
75,996
97,672
97,67275,996106,481146,590206,66788,930112,245105,948132,275159,969192,528182,518324,47543,326104,79759,50063,00253,29838,36425,70421,05223,28212,91017,58300020,594
       Short-term Investments 
0
0
0
0
43,968
39,119
124,612
120,751
109,107
82,435
56,581
117,877
109,055
156,962
201,320
168,797
293,784
265,803
275,802
287,897
289,707
282,837
282,890
409,707
436,796
432,619
420,765
368,679
368,679420,765432,619436,796409,707282,890282,837289,707287,897275,802265,803293,784168,797201,320156,962109,055117,87756,58182,435109,107120,751124,61239,11943,9680000
       Net Receivables 
1,407
0
0
0
2,389
2,251
2,221
1,843
2,474
2,410
2,337
4,775
2,962
2,951
3,081
2,121
2,953
2,968
2,887
2,210
3,055
2,825
2,589
1,996
2,939
3,047
2,900
4,295
4,2952,9003,0472,9391,9962,5892,8253,0552,2102,8872,9682,9532,1213,0812,9512,9624,7752,3372,4102,4741,8432,2212,2512,3890001,407
       Other Current Assets 
401
0
0
0
763
944
1,752
3
3,696
4,529
5,796
5,220
2,734
3,031
4,687
4,035
4,492
3,264
5,726
5,413
5,267
4,040
4,981
5,591
6,278
7,895
8,514
8,518
8,5188,5147,8956,2785,5914,9814,0405,2675,4135,7263,2644,4924,0354,6873,0312,7345,2205,7964,5293,69631,752944763000401
   > Long-term Assets 
0
0
0
0
448
4,069
1,949
7,241
13,345
15,803
33,426
59,549
59,846
61,842
61,830
59,770
59,351
59,161
59,080
57,487
57,215
57,480
56,705
54,589
53,988
53,849
54,223
53,766
53,76654,22353,84953,98854,58956,70557,48057,21557,48759,08059,16159,35159,77061,83061,84259,84659,54933,42615,80313,3457,2411,9494,0694480000
       Property Plant Equipment 
342
0
0
0
370
443
420
6,055
12,159
1,653
15,506
57,913
58,210
59,527
58,732
58,134
57,715
56,744
55,977
55,851
55,579
55,023
53,773
52,953
52,352
51,811
51,778
52,130
52,13051,77851,81152,35252,95353,77355,02355,57955,85155,97756,74457,71558,13458,73259,52758,21057,91315,5061,65312,1596,055420443370000342
       Intangible Assets 
0
0
0
0
0
0
0
0
0
613
1,212
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,212613000000000
       Long-term Assets Other 
0
0
0
0
78
3,626
1,529
1,186
1,186
14,150
17,920
1,636
1,636
2,315
3,098
1,636
1,636
2,417
3,103
1,636
1,636
2,457
2,932
1,636
1,636
0
2,445
1,636
1,6362,44501,6361,6362,9322,4571,6361,6363,1032,4171,6361,6363,0982,3151,6361,63617,92014,1501,1861,1861,5293,626780000
> Total Liabilities 
2,725
0
0
0
93,219
97,992
3,780
8,948
16,470
13,389
30,797
52,858
50,379
51,769
52,854
43,003
44,370
44,700
46,052
47,773
49,963
49,165
52,023
83,205
91,299
89,862
97,226
111,393
111,39397,22689,86291,29983,20552,02349,16549,96347,77346,05244,70044,37043,00352,85451,76950,37952,85830,79713,38916,4708,9483,78097,99293,2190002,725
   > Total Current Liabilities 
1,985
0
0
0
5,164
4,496
3,744
3,808
9,885
13,053
11,982
14,217
11,874
11,878
12,965
13,018
14,547
15,049
16,636
18,291
20,756
20,314
23,537
26,464
33,825
32,242
39,832
38,650
38,65039,83232,24233,82526,46423,53720,31420,75618,29116,63615,04914,54713,01812,96511,87811,87414,21711,98213,0539,8853,8083,7444,4965,1640001,985
       Short-term Debt 
0
0
0
0
0
0
0
0
0
394
665
3,404
3,284
3,259
3,346
3,434
3,457
3,481
3,491
3,615
3,632
3,617
3,602
3,658
3,757
3,797
3,816
3,861
3,8613,8163,7973,7573,6583,6023,6173,6323,6153,4913,4813,4573,4343,3463,2593,2843,404665394000000000
       Accounts payable 
323
0
0
0
1,993
2,854
2,072
1,501
7,084
10,830
7,965
6,256
3,434
3,480
2,374
2,350
2,355
2,382
3,154
3,922
3,732
4,482
3,996
3,648
5,364
4,883
4,365
3,903
3,9034,3654,8835,3643,6483,9964,4823,7323,9223,1542,3822,3552,3502,3743,4803,4346,2567,96510,8307,0841,5012,0722,8541,993000323
       Other Current Liabilities 
1,662
0
0
0
3,171
1,642
1,672
2,307
2,801
1,829
3,352
4,557
5,156
5,139
7,245
7,234
8,735
9,186
9,991
10,754
1,320
1,048
2,516
1,146
2,994
2,997
3,891
3,561
3,5613,8912,9972,9941,1462,5161,0481,32010,7549,9919,1868,7357,2347,2455,1395,1564,5573,3521,8292,8012,3071,6721,6423,1710001,662
   > Long-term Liabilities 
0
0
0
0
88,055
93,496
36
5,140
6,585
336
18,815
38,641
38,505
39,891
39,889
29,985
29,823
29,651
29,416
29,482
29,207
28,851
28,486
56,741
57,474
57,620
57,394
72,743
72,74357,39457,62057,47456,74128,48628,85129,20729,48229,41629,65129,82329,98539,88939,89138,50538,64118,8153366,5855,1403693,49688,0550000
       Long term Debt Total 
0
0
0
0
0
0
0
0
6,561
0
14,431
34,755
34,768
9,764
9,827
0
0
0
0
0
0
0
0
28,390
0
28,905
0
0
0028,905028,390000000009,8279,76434,76834,75514,43106,56100000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
336
9,156
28,902
28,704
30,127
30,062
29,985
29,823
29,651
29,416
29,482
29,207
28,851
28,486
28,351
28,354
28,137
27,761
27,516
27,51627,76128,13728,35428,35128,48628,85129,20729,48229,41629,65129,82329,98530,06230,12728,70428,9029,156336000000000
       Warrants
0
0
0
0
0
86,361
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000086,36100000
       Long-term Liabilities Other 
0
0
0
0
0
7,092
0
4,972
6,561
336
9,156
28,902
28,704
30,127
30,062
29,985
29,823
29,651
29,416
29,482
0
28,851
28,486
28,351
472
28,715
472
793
79347228,71547228,35128,48628,851029,48229,41629,65129,82329,98530,06230,12728,70428,9029,1563366,5614,97207,09200000
       Deferred Long Term Liability 
0
0
0
0
0
43
36
168
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000024168364300000
> Total Stockholder Equity
20,094
-11,515
0
0
-28,068
-38,699
150,036
143,239
137,856
130,152
120,641
197,565
183,718
277,814
261,390
516,195
498,728
479,024
457,412
437,509
411,229
410,262
384,072
595,345
555,292
514,029
465,172
421,537
421,537465,172514,029555,292595,345384,072410,262411,229437,509457,412479,024498,728516,195261,390277,814183,718197,565120,641130,152137,856143,239150,036-38,699-28,06800-11,51520,094
   Common Stock
5
0
0
0
5
5
32
32
32
32
32
37
37
40
40
46
47
47
47
47
47
49
50
57
57
57
59
61
61595757575049474747474746404037373232323232550005
   Retained Earnings Total Equity00-535,0430-436,249-396,559-353,4570-279,508-249,834-220,479-193,168-171,669-149,886-129,791-112,298-96,509-80,320-69,181-59,766-53,110-45,437-38,97600000
   Accumulated Other Comprehensive Income 
0
0
0
0
-238
-1,050
-1,223
-1,380
-1,055
-1,172
-1,430
-1,047
-982
-1,190
-611
-116
-394
-210
9
-181
-973
520
2,931
3,739
5,729
3,966
5,488
4,734
4,7345,4883,9665,7293,7392,931520-973-1819-210-394-116-611-1,190-982-1,047-1,430-1,172-1,055-1,380-1,223-1,050-2380000
   Capital Surplus 
0
0
0
0
0
1,322
196,664
197,697
198,645
200,473
202,359
295,084
296,961
408,755
411,847
687,934
692,243
699,666
707,190
717,151
0
763,150
777,650
1,027,798
0
1,045,049
0
0
001,045,04901,027,798777,650763,1500717,151707,190699,666692,243687,934411,847408,755296,961295,084202,359200,473198,645197,697196,6641,32200000
   Treasury Stock0000000000000000000000000000
   Other Stockholders Equity 
-2,549
0
0
0
1,097
1,322
196,664
197,697
198,645
200,473
202,359
295,084
296,961
408,755
411,847
687,934
692,243
699,666
707,190
717,151
723,359
763,150
777,650
1,027,798
1,034,994
1,045,049
1,054,712
1,062,949
1,062,9491,054,7121,045,0491,034,9941,027,798777,650763,150723,359717,151707,190699,666692,243687,934411,847408,755296,961295,084202,359200,473198,645197,697196,6641,3221,097000-2,549



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-2,447
Gross Profit-2,447-2,447
 
Operating Income (+$)
Gross Profit-2,447
Operating Expense-174,166
Operating Income-177,080-176,613
 
Operating Expense (+$)
Research Development126,527
Selling General Administrative50,553
Selling And Marketing Expenses0
Operating Expense174,166177,080
 
Net Interest Income (+$)
Interest Income0
Interest Expense-4,160
Other Finance Cost-0
Net Interest Income-4,160
 
Pretax Income (+$)
Operating Income-177,080
Net Interest Income-4,160
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-173,996-181,410
EBIT - interestExpense = -184,002
-173,996
-170,124
Interest Expense4,160
Earnings Before Interest and Taxes (EBIT)-179,842-169,836
Earnings Before Interest and Taxes (EBITDA)-177,395
 
After tax Income (+$)
Income Before Tax-173,996
Tax Provision-288
Net Income From Continuing Ops-174,284-174,284
Net Income-174,284
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses174,166
Total Other Income/Expenses Net4,3304,160
 

Technical Analysis of Replimune
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Replimune. The general trend of Replimune is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Replimune's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Replimune Group Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.09 < 9.2 < 9.5.

The bearish price targets are: 6.775 > 6.75 > 5.89.

Tweet this
Replimune Group Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Replimune Group Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Replimune Group Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Replimune Group Inc. The current macd is -0.06296103.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Replimune price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Replimune. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Replimune price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Replimune Group Inc Daily Moving Average Convergence/Divergence (MACD) ChartReplimune Group Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Replimune Group Inc. The current adx is 20.26.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Replimune shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Replimune Group Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Replimune Group Inc. The current sar is 8.60873526.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Replimune Group Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Replimune Group Inc. The current rsi is 47.58. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Replimune Group Inc Daily Relative Strength Index (RSI) ChartReplimune Group Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Replimune Group Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Replimune price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Replimune Group Inc Daily Stochastic Oscillator ChartReplimune Group Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Replimune Group Inc. The current cci is -59.84414679.

Replimune Group Inc Daily Commodity Channel Index (CCI) ChartReplimune Group Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Replimune Group Inc. The current cmo is -7.10586664.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Replimune Group Inc Daily Chande Momentum Oscillator (CMO) ChartReplimune Group Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Replimune Group Inc. The current willr is -52.28426396.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Replimune is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Replimune Group Inc Daily Williams %R ChartReplimune Group Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Replimune Group Inc.

Replimune Group Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Replimune Group Inc. The current atr is 0.48765501.

Replimune Group Inc Daily Average True Range (ATR) ChartReplimune Group Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Replimune Group Inc. The current obv is -21,130,739.

Replimune Group Inc Daily On-Balance Volume (OBV) ChartReplimune Group Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Replimune Group Inc. The current mfi is 24.71.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Replimune Group Inc Daily Money Flow Index (MFI) ChartReplimune Group Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Replimune Group Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-21MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Replimune Group Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Replimune Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.577
Ma 20Greater thanMa 508.523
Ma 50Greater thanMa 1008.098
Ma 100Greater thanMa 2008.751
OpenGreater thanClose8.230
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Replimune with someone you think should read this too:
  • Are you bullish or bearish on Replimune? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Replimune? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Replimune Group Inc

I send you an email if I find something interesting about Replimune Group Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Replimune Group Inc.

Receive notifications about Replimune Group Inc in your mailbox!